Synthetic gene circuits moving into the clinic

On November 28th 2020,SyngenTech,a China-based biotechnology company,announced that the company’s leading oncolytic virotherapeutic product,SynOVl.l,was approved for clinical trial by the U.S.Food and Drug Administration.After synthetic bacterial or cell therapy[1,2],this is the first introduction of a viral therapy engineered using synthetic gene circuits into the clinic.Together with the clinical development of variable living therapeutics,we anticipate that synthetic gene circuits will receive increasing attention as a revolutionary technology to improve disease-treatment efficacy.